Clinical Trial

Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety and efficacy of first-line, risk-stratified Rituximab-based Multicentric Castleman Disease (MCD) treatment in Malawi in a single-arm, phase II clinical trial. This study also aims to compare the cost-effectiveness of first-line Rituximab treatment for MCD in Malawi to chemotherapy.
Protocol Amendment History 1 change
critical Trial completed 2026-07-31
Trial Details
NCT Number NCT04585893
Lead Sponsor UNC Lineberger Comprehensive Cancer Center
Collaborators: Fogarty International Center of the National Institute of Health
Conditions Multicentric Castleman Disease
Enrollment 15 participants
Start Date 2021-06-22
Primary Completion 2024-08-30 (estimated)
Study Completion 2026-06-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-30